Lurie Cancer Center Member
Andrew P Mazar, PhD
Research Professor, Pharmacology; Feinberg School of Medicine
Cancer and Physical Sciences
View Publications Listing
Dr. Mazar's research has focused on the role of the plasminogen activator system in tumor progression with a specific focus on the urokinase plasminogen activator receptor (uPAR). Dr. Mazar's group has elucidated a number of uPAR's structure-function relationships involved in tumor progression and has designed several therapeutics targeting these interactions. One of these, a humanized monoclonal antibody called ATN-658, is now being developed for the clinic in collaboration with the NCI NExT program. A second uPA targeting antibody, ATN-291, that is internalized via endocytosis by tumor cells is being evaluated for targeting cytotoxics and imaging agents to tumors. In collaboration with investigators at the University of Texas, Dr. Mazar also recently received support from the NHLBI SMARTT program for IND-enabling studies of the proenzyme form of urokinase for the treatment of complicated parapneumonic effusions. Dr. Mazar also has extensive expertise in oncology drug development and collaborates with numerous groups within the Cancer Center and at other academic institutions as well as with industry on the discovery and early development of novel cancer therapeutics.